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Background: Diabetes mellitus is associated with adverse outcomes after stent implantation. Thiazolidinediones (TZDs), insulin-sensitizing agents, 
have anti-inflammatory, anti-proliferative and anti-atherosclerotic properties. Current literature demonstrates potential benefit of TZDs in prevention 
of atherosclerosis and restenosis. We undertook this study to examine the effectiveness of TZDs on reduction of cardiovascular events and mortality 
after DES implantation.
Methods: 1719 diabetic patients who underwent PCI with DES implantation between 2001 and 2010 were selected and were divided into 
two groups. Patients in treatment group were given TZDs (pioglitazone or rosiglitazone) on discharge (n=376) while those in control group were 
not prescribed TZDs (n=1343). Patients were followed for three years for clinical events such as cardiac death, myocardial infarction, need for 
revascularization, sub acute stent thrombosis and all cause mortality. A composite outcome of death and Q wave MI at one year was the primary 
outcome.
Results: Prescription of TZDs on discharge was associated with significantly lower mortality (composite outcome of death and Q wave MI) at 1 year 
follow up among diabetic patients (2.4% Vs 7.8%, P<0.001). This finding remained significant in the multivariate analysis even after adjusting for 
confounding factors. Moreover, incidence of MACE (Death, MI and TVR) was also significantly lower in treatment group (12.5% Vs 16.8%, P=0.04). The 
incidences of MI, revascularization procedures and stent thrombosis were similar between two groups.
Conclusions: In conclusion, though prescription of TZDs on discharge was not associated with significant reduction in MI, need for TVR or stent 
thrombosis, it was found to be associated with lower mortality. Randomized controlled trial is needed to evaluate the benefit of TZDs after DES 
implantation.
